THERAVANCE BIOPHARMA INC (TBPH) Stock Analyst Earnings Estimates
NASDAQ:TBPH - Nasdaq - KYG8807B1068 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 55.3M -23.09% | 51.3M -7.23% | 57.424M 11.94% | 63.974M 11.41% | 87.875M 37.36% | 100.76M 14.66% | 138.36M 37.32% | 177.11M 28.01% | 264.38M 49.27% | 326.18M 23.38% | 611.9M 87.60% | 304.98M -50.16% | |
| EBITDA YoY % growth | -231.79M 20.29% | -75.38M 67.48% | -47.139M 37.46% | -11.884M 74.79% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -237.7M 20.13% | -79.1M 66.72% | -53.292M 32.63% | -47.889M 10.14% | -25.398M 46.96% | -42.809M -68.55% | -20.294M 52.59% | 24.369M 220.08% | 107.7M 341.95% | 164.44M 52.68% | 604.39M 267.54% | N/A | |
| Operating Margin | -429.84% | -154.19% | -92.80% | -74.86% | -28.90% | -42.49% | -14.67% | 13.76% | 40.74% | 50.41% | 98.77% | N/A | |
| EPS YoY % growth | -2.95 34.15% | -0.67 77.29% | -0.97 -44.78% | -1.08 -11.46% | 0.11 110.02% | -0.09 -184.94% | 0.44 576.45% | 1.64 273.26% | 3.62 120.87% | 4.90 35.40% | 7.40 51.15% | 2.88 -61.13% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.21 -26.00% | -0.22 6.50% | -0.21 25.32% | -0.20 21.54% | 0.13 161.90% |
| Revenue Q2Q % growth | 17.419M -0.83% | 16.422M 13.23% | 16.558M 16.15% | 20.604M 22.15% | 47.328M 171.70% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -10.302M -65.10% | -12.24M -9.22% | -13.056M -2.37% | -11.22M -20.97% | 6.273M 160.89% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.26 -52.94% | -0.24 | -0.02 | -10.35% |
| Q2 2024 Q2Q % growth | -0.28 | -0.21 | -0.07 | -32.93% |
| Q1 2024 Q2Q % growth | -0.24 31.43% | -0.26 | 0.02 | 7.36% |
| Q4 2023 Q2Q % growth | -0.17 -13.33% | -0.15 | -0.02 | -12.11% |
| Q3 2023 Q2Q % growth | -0.17 19.05% | -0.21 | 0.04 | 20.51% |
| Q2 2023 Q2Q % growth | -0.28 -211.11% | -0.21 | -0.07 | -30.72% |
| Q1 2023 Q2Q % growth | -0.35 -59.09% | -0.25 | -0.10 | -39.30% |
| Q4 2022 Q2Q % growth | -0.15 65.12% | -0.18 | 0.03 | 14.75% |
| Q3 2022 Q2Q % growth | -0.21 56.25% | -0.19 | -0.02 | -12.81% |
| Q2 2022 Q2Q % growth | -0.09 88.75% | 0.11 | -0.20 | -180.95% |
| Q1 2022 Q2Q % growth | -0.22 82.26% | -0.11 | -0.11 | -103.48% |
| Q4 2021 Q2Q % growth | -0.43 53.26% | -0.34 | -0.09 | -27.17% |
| Q3 2021 Q2Q % growth | -0.48 58.62% | -0.57 | 0.09 | 15.80% |
| Q2 2021 Q2Q % growth | -0.80 20.00% | -1.02 | 0.22 | 21.48% |
| Q1 2021 Q2Q % growth | -1.24 11.43% | -1.07 | -0.17 | -15.99% |
| Q4 2020 Q2Q % growth | -0.92 21.37% | -1.04 | 0.12 | 11.21% |
| Q3 2020 Q2Q % growth | -1.16 -10.48% | -1.03 | -0.13 | -12.28% |
| Q2 2020 Q2Q % growth | -1.00 -38.89% | -1.00 | 0.00 | -0.42% |
| Q1 2020 Q2Q % growth | -1.40 -6.06% | -1.10 | -0.30 | -27.68% |
| Q4 2019 Q2Q % growth | -1.17 | -1.15 | -0.02 | -1.36% |
| Q3 2019 Q2Q % growth | -1.05 | -1.13 | 0.08 | 6.98% |
| Q2 2019 Q2Q % growth | -0.72 | -1.26 | 0.54 | 42.88% |
| Q1 2019 Q2Q % growth | -1.32 | -1.21 | -0.11 | -8.75% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 16.868M 7.49% | 15.65M | 1.218M | 7.78% |
| Q2 2024 Q2Q % growth | 14.256M 3.69% | 15.762M | -1.506M | -9.55% |
| Q1 2024 Q2Q % growth | 14.503M 39.22% | 14.242M | 261K | 1.83% |
| Q4 2023 Q2Q % growth | 17.565M 20.31% | 18.038M | -473K | -2.62% |
| Q3 2023 Q2Q % growth | 15.693M 25.54% | 15.302M | 391K | 2.56% |
| Q2 2023 Q2Q % growth | 13.749M 23.86% | 15.729M | -1.98M | -12.59% |
| Q1 2023 Q2Q % growth | 10.417M -21.08% | 13.988M | -3.571M | -25.53% |
| Q4 2022 Q2Q % growth | 14.6M -2.01% | 16.041M | -1.441M | -8.98% |
| Q3 2022 Q2Q % growth | 12.5M -5.30% | 12.046M | 454K | 3.77% |
| Q2 2022 Q2Q % growth | 11.1M -13.95% | 12.661M | -1.561M | -12.33% |
| Q1 2022 Q2Q % growth | 13.2M -7.69% | 14.774M | -1.574M | -10.65% |
| Q4 2021 Q2Q % growth | 14.9M -20.32% | 13.751M | 1.149M | 8.36% |
| Q3 2021 Q2Q % growth | 13.2M -27.87% | 14.689M | -1.489M | -10.14% |
| Q2 2021 Q2Q % growth | 12.9M -14.00% | 15.715M | -2.815M | -17.91% |
| Q1 2021 Q2Q % growth | 14.3M -28.14% | 17.615M | -3.315M | -18.82% |
| Q4 2020 Q2Q % growth | 18.7M -36.61% | 21.263M | -2.563M | -12.05% |
| Q3 2020 Q2Q % growth | 18.3M 47.58% | 18.945M | -645K | -3.40% |
| Q2 2020 Q2Q % growth | 15M -42.75% | 20.033M | -5.033M | -25.12% |
| Q1 2020 Q2Q % growth | 19.9M 275.47% | 18.49M | 1.41M | 7.63% |
| Q4 2019 Q2Q % growth | 29.5M | 17.172M | 12.328M | 71.79% |
| Q3 2019 Q2Q % growth | 12.4M | 11.856M | 544K | 4.59% |
| Q2 2019 Q2Q % growth | 26.2M | 11.083M | 15.117M | 136.40% |
| Q1 2019 Q2Q % growth | 5.3M | 16.54M | -11.24M | -67.96% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | -3600% | 0% | -4.5% |
| Revenue | 0% | -36.08% | 0% | 4.19% |